AXM Pharma Appoints Experienced Executives to Board of Directors; CFO of Nasdaq-listed Company to Serve as Chairman of Audit Co
09 3월 2006 - 11:20PM
Business Wire
AXM Pharma, Inc. (AMEX: AXJ), (the "Company") a manufacturer of
proprietary and generic pharmaceutical and nutraceutical products
for the Chinese and other Asian markets, announced today that it
has elected Elliot M. Maza and Wenzhou Zhang to serve as
independent directors of the Company. Elliot M. Maza, who is
currently Chief Financial Officer of Emisphere Technologies, Inc.
(NASDAQ: EMIS), a biopharmaceutical company, will also serve as the
Chairman of the Audit Committee. During his career, Mr. Maza has
held distinguished positions in the areas of finance and law. While
at Emisphere, he has successfully restructured the company's
indebtedness, helped the company raise capital and implemented
Section 404 under the Sarbases-Oxley Act. Since December 2004, he
has also served as a member of the Board of Directors and chairman
of the audit committee of Tapestry Pharmaceuticals Inc. (NASDAQ:
TPPH). Previously, he was a Partner at Ernst and Young LLP and a
Vice President at Goldman Sachs, JP. Morgan Securities and BT
Securities Corporation. Mr. Maza previously practiced law at
Sullivan and Cromwell LLP. He received his J.D. degree from the
University of Pennsylvania Law School in 1985 and his C.P.A. from
the State of New Jersey in 1981 Mr. Zhang has 38 years of
pharmaceutical industry experience and management experience in
China. For the past 10 years, he has served as a Vice Official to
the State Food and Drug Administration and the State Drug
Administration in China. Previous to that time, Mr. Zhang served as
the Secretary of Chongqing Municipality, the Chairman of the
Chongqing Economic Reform Committee, an official of Chongqing Drug
Administration, and as a General Manager of Chongqing
Pharmaceutical Factory. "We are pleased to attract two such
seasoned executives to our board of directors," said Wang Weishi,
AXM's Chief Executive Officer. "We have recently made significant
progress in capital-raising activities, and believe that Elliot and
Wenzhou will play a key role in helping us move the Company forward
so that we can capitalize on the significant opportunities in the
Chinese and other Asian markets to manufacturer our proprietary and
generic pharmaceutical and nutraceutical products." About AXM
Pharma, Inc. AXM Pharma, Inc., through its wholly owned subsidiary,
AXM Pharma Shenyang, Inc. ("AXM Shenyang"), is a manufacturer of
proprietary and generic pharmaceutical products, which include
injectables, capsules, tablets, liquids and medicated skin products
for export and domestic Chinese sales. AXM Shenyang is located in
the City of Shenyang, in the Province of Liaoning, China. AXM
Shenyang has an operating history of approximately 10 years. For
additional information on AXM Pharma Inc., please visit
http://www.axmpharma.com. Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: The statements contained
in this news release include certain predictions and projections
that may be considered forward-looking statements under securities
law, including the statements regarding the Company's opportunities
for future growth. These statements involve a number of important
risks and uncertainties that could cause actual results to differ
materially including, but not limited to, the performance of joint
venture partners, obtaining regulatory approvals to market the
Company's products, the uncertainties associated with distributing
products in a developing country such as China, the availability of
cash to meet near term requirements as well as other economic,
competitive and technological factors involving the Company's
operations, markets, services, products and prices. With respect to
AXM, except for the historical information contained herein, the
matters discussed in this news release are forward-looking
statements involving risks and uncertainties that could cause
actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, AXM's extremely limited operating
history, uncertainties related to the Company's access to
additional capital, competition and dependence on key management.
Axm (AMEX:AXJ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Axm (AMEX:AXJ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024